Neuropore Therapies Inc, a biopharmaceutical company discovering and developing novel therapeutics for the treatment of Parkinson’s disease and other neurodegenerative disorders, announces that it has received a $4.8M grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grant will be used to support the preclinical and clinical development a of a novel brain-penetrating small molecule Toll-Like receptor 2 (TLR2) antagonist.
“We are very pleased to receive such a significant funding award from The Michael J. Fox Foundation. TLR2 plays an important role in creating and maintaining a harmful neuro-inflammatory condition in Parkinson’s disease. Reducing this neuroinflammation, by blocking TLR2, has the potential to prevent neurodegeneration and slow the progression of the disease. This grant will help enable us to rapidly advance our lead TLR2 antagonist through preclinical and early clinical development,” stated Douglas Bonhaus, Chief Executive Officer of Neuropore Therapies Inc.
Neuropore Therapies Inc is a San Diego-based biopharmaceutical company developing novel disease modifying small molecule therapeutics for the treatment of Parkinson’s disease and other neurodegenerative disorders by targeting underlying mechanisms related to protein pathology and neuroinflammation.
[Source(s): Neuropore Therapies, Business Wire]
Related Content:
The Michael J. Fox Foundation Launches the Bachmann-Strauss Fellowship in Dystonia Research
Fox Foundation Grant Aims to Help Lucy Therapeutics Unlock Secrets of Mitochondria in Parkinson’s Disease
